Apogee Therapeutics announced compelling Phase 2 data for APG777, its anti-IL-13 antibody targeting atopic dermatitis. The drug significantly reduced disease severity versus placebo and demonstrated skin clearance rates exceeding those of current competing biologics like Dupixent and Ebglyss. APG777’s extended half-life could enable dosing as infrequent as twice yearly, offering a potential advantage in convenience and adherence. A larger Phase 3 trial is planned, targeting a crowded market with strong clinical differentiation.